Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

--On pace for largest percent decrease since Oct. 27, 2023, when it fell 19.13% --Down 9.68% month-to-date; on pace for worst month since Oct. 2023, when it fell 15.64% --Down 16.48% from its all-time ...